1 week Ago By ABMN Staff
SVB Wealth LLC lowered its holdings in Bio-Techne Co. ( NASDAQ:TECH – Free Report ) by 62.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission.
The institutional investor owned 25,844 shares of the biotechnology company’s stock after selling 42,605 shares during the period. SVB Wealth LLC’s holdings in Bio-Techne were worth $1,852,000 as of its most recent SEC filing. Several other large investors also recently made changes to their positions in TECH.
Private Advisor Group LLC boosted its stake in shares of Bio-Techne by 109.1% in the second quarter. Private Advisor Group LLC now owns 20,978 shares of the biotechnology company’s stock valued at $1,503,000 after purchasing an additional 10,947 shares during the period.
Parkside Financial Bank & Trust boosted its stake in shares of Bio-Techne by 6.3% in the second quarter. Parkside Financial Bank & Trust now owns 3,943 shares of the biotechnology company’s stock valued at $283,000 after purchasing an additional 232 shares during the period.
Summit Creek Advisors LLC boosted its stake in shares of Bio-Techne by 11.4% in the second quarter. Summit Creek Advisors LLC now owns 250,489 shares of the biotechnology company’s stock valued at $17,948,000 after purchasing an additional 25,726 shares during the period.
Kornitzer Capital Management Inc. KS boosted its stake in shares of Bio-Techne by 0.5% in the second quarter.
Kornitzer Capital Management Inc. KS now owns 231,435 shares of the biotechnology company’s stock valued at $16,582,000 after purchasing an additional 1,060 shares during the period. Finally, National Bank of Canada FI boosted its stake in shares of Bio-Techne by 24.
4% in the second quarter. National Bank of Canada FI now owns 43,255 shares of the biotechnology company’s stock valued at $3,097,000 after purchasing an additional 8,491 shares during the period. Institutional investors and hedge funds own 98.
95% of the company’s stock. Bio-Techne Trading Down 1.2 % Bio-Techne stock opened at $71.
49 on Monday. The firm’s 50-day moving average is $74.72 and its 200-day moving average is $73.
85. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.
75 and a current ratio of 3.87. Bio-Techne Co.
has a 1 year low of $51.79 and a 1 year high of $85.57.
The company has a market cap of $11.34 billion, a P/E ratio of 56.74, a PEG ratio of 4.
98 and a beta of 1.27. Bio-Techne Dividend Announcement The company also recently disclosed a quarterly dividend, which was paid on Friday, August 30th.
Investors of record on Monday, August 19th were issued a $0.08 dividend. The ex-dividend date was Monday, August 19th.
This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.45%.
Bio-Techne’s dividend payout ratio (DPR) is presently 25.40%. Analyst Ratings Changes TECH has been the subject of several analyst reports.
Citigroup downgraded shares of Bio-Techne from a “buy” rating to a “neutral” rating and set a $85.00 target price for the company. in a research note on Wednesday, May 22nd.
Benchmark reiterated a “buy” rating and set a $95.00 price objective on shares of Bio-Techne in a research note on Tuesday, August 13th. Royal Bank of Canada reduced their price objective on shares of Bio-Techne from $72.
00 to $70.00 and set a “sector perform” rating on the stock in a research note on Thursday, August 8th. Finally, Robert W.
Baird increased their price objective on shares of Bio-Techne from $81.00 to $82.00 and gave the company an “outperform” rating in a research note on Thursday, August 8th.
Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, Bio-Techne presently has a consensus rating of “Moderate Buy” and a consensus target price of $80.60.
Get Our Latest Analysis on TECH Bio-Techne Profile ( Free Report ) Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. See Also Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter .
.
